Melissa J J Voorn1,2,3, Loes P A Aerts4, Gerbern P Bootsma5, Jacques B Bezuidenhout6, Vivian E M van Kampen-van den Boogaart7, Bart C Bongers8,9, Dirk K de Ruysscher10, Maryska L G Janssen-Heijnen11,12. 1. Department of Clinical Epidemiology, VieCuri Medical Centre, Tegelseweg 210, 5912 BL, Venlo, The Netherlands. mvoorn@viecuri.nl. 2. Adelante Rehabilitation Centre, Venlo, The Netherlands. mvoorn@viecuri.nl. 3. Department of Epidemiology, GROW School for Oncology and Developmental Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. mvoorn@viecuri.nl. 4. Funqtio, Venlo, The Netherlands. 5. Department of Pulmonology, Zuyderland Medical Centre, Heerlen, The Netherlands. 6. Department of Radiation Oncology, University Hospital Brussels, Brussels, Belgium. 7. Department of Pulmonology, VieCuri Medical Centre, Venlo, The Netherlands. 8. Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. 9. Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. 10. Department of Radiation Oncology (MAASTRO Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. 11. Department of Clinical Epidemiology, VieCuri Medical Centre, Tegelseweg 210, 5912 BL, Venlo, The Netherlands. 12. Department of Epidemiology, GROW School for Oncology and Developmental Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Abstract
OBJECTIVE: The aim of this study was to evaluate associations between pretreatment physical status parameters and tolerance of concurrent chemoradiation (cCHRT) and survival among patients with stage III non-small cell lung cancer (NSCLC). METHODS: A retrospective cohort study was conducted among patients with stage III NSCLC who had received cCHRT between 2006 and 2015. Multivariate independent associations were analysed between the pretreatment parameters age, Charlson comorbidity index, World Health Organization performance status (WHO performance status), body mass index (BMI), fat-free mass index (FFMI), maximal handgrip strength, forced expiratory volume in one second and carbon monoxide lung diffusion capacity on the one hand with tolerance of cCHRT (defined as a received radiation dose at least equal to the prescribed radiation dose) and survival on the other hand. RESULTS: 527 of 577 patients (91.3%) tolerated cCHRT. A WHO performance status ≥ 2 (odds ratio (OR) 0.43) and BMI < 18.5 kg/m2 (OR 0.36) were associated with poorer tolerance of cCHRT. In the total group, a WHO performance status ≥ 2 (hazard ratio (HR) 1.73), low FFMI (HR 1.23) and intolerance of cCHRT (HR 1.55) were associated with poorer survival. CONCLUSION: In patients with stage III NSCLC receiving cCHRT, poor WHO performance status and BMI < 18.5 kg/m2 were independently associated with tolerance of cCHRT. Physical status parameters and intolerance of cCHRT were independently associated with poorer survival. Besides using this information for treatment decisions, optimizing physical status in patients at risk for intolerance of cCHRT might be a next step for improving treatment outcomes.
OBJECTIVE: The aim of this study was to evaluate associations between pretreatment physical status parameters and tolerance of concurrent chemoradiation (cCHRT) and survival among patients with stage III non-small cell lung cancer (NSCLC). METHODS: A retrospective cohort study was conducted among patients with stage III NSCLC who had received cCHRT between 2006 and 2015. Multivariate independent associations were analysed between the pretreatment parameters age, Charlson comorbidity index, World Health Organization performance status (WHO performance status), body mass index (BMI), fat-free mass index (FFMI), maximal handgrip strength, forced expiratory volume in one second and carbon monoxide lung diffusion capacity on the one hand with tolerance of cCHRT (defined as a received radiation dose at least equal to the prescribed radiation dose) and survival on the other hand. RESULTS: 527 of 577 patients (91.3%) tolerated cCHRT. A WHO performance status ≥ 2 (odds ratio (OR) 0.43) and BMI < 18.5 kg/m2 (OR 0.36) were associated with poorer tolerance of cCHRT. In the total group, a WHO performance status ≥ 2 (hazard ratio (HR) 1.73), low FFMI (HR 1.23) and intolerance of cCHRT (HR 1.55) were associated with poorer survival. CONCLUSION: In patients with stage III NSCLC receiving cCHRT, poor WHO performance status and BMI < 18.5 kg/m2 were independently associated with tolerance of cCHRT. Physical status parameters and intolerance of cCHRT were independently associated with poorer survival. Besides using this information for treatment decisions, optimizing physical status in patients at risk for intolerance of cCHRT might be a next step for improving treatment outcomes.
Authors: L Decoster; C Kenis; D Schallier; J Vansteenkiste; K Nackaerts; L Vanacker; N Vandewalle; J Flamaing; J P Lobelle; K Milisen; J De Grève; H Wildiers Journal: Lung Date: 2017-06-20 Impact factor: 2.584
Authors: M T E Puts; B Santos; J Hardt; J Monette; V Girre; E G Atenafu; E Springall; S M H Alibhai Journal: Ann Oncol Date: 2013-11-19 Impact factor: 32.976
Authors: Elisabeth J M Driessen; Judith G M van Loon; Huub A Maas; Anne-Marie C Dingemans; Maryska L G Janssen-Heijnen Journal: Lung Date: 2018-04-12 Impact factor: 2.584
Authors: Francesco Cuccia; Gianluca Mortellaro; Rosario Mazzola; Alessandra Donofrio; Vito Valenti; Antonella Tripoli; Domenica Matranga; Antonio Lo Casto; Giuseppe Failla; Giuseppe Di Miceli; Giuseppe Ferrera Journal: J Geriatr Oncol Date: 2019-05-20 Impact factor: 3.599
Authors: Karlijn J G Schulkes; Esteban T D Souwer; Leontine J R van Elden; Henk Codrington; Simone van der Sar-van der Brugge; Jan-Willem J Lammers; Johanneke E A Portielje; Frederiek van den Bos; Marije E Hamaker Journal: Clin Lung Cancer Date: 2017-03-02 Impact factor: 4.785
Authors: Elisabeth J M Driessen; Gerbern P Bootsma; Lizza E L Hendriks; Franchette W P J van den Berkmortel; Brigitte A H A Bogaarts; Judith G M van Loon; Anne-Marie C Dingemans; Maryska L G Janssen-Heijnen Journal: Radiother Oncol Date: 2016-08-10 Impact factor: 6.280
Authors: Céline M H Op den Kamp; Dirk K M De Ruysscher; Marieke van den Heuvel; Meike Elferink; Ruud M A Houben; Cary J G Oberije; Gerben P Bootsma; Wiel H Geraedts; Cordula C M Pitz; Ramon C Langen; Emiel F M Wouters; Annemie M W J Schols; Anne-Marie C Dingemans Journal: J Cachexia Sarcopenia Muscle Date: 2014-01-23 Impact factor: 12.910
Authors: Melissa J J Voorn; Bart C Bongers; Vivian E M van Kampen-van den Boogaart; Elisabeth J M Driessen; Maryska L G Janssen-Heijnen Journal: Cancers (Basel) Date: 2022-05-12 Impact factor: 6.575